Aurobindo Pharma signs non-exclusive voluntary license agreement with MSD

Aurobindo Pharma Limited is pleased to announce that it has entered into a non-exclusive voluntary licensing agreement with MSD (trade name of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK). Aurobindo Pharma is among a select group of global generic manufacturers to have signed this agreement. The royalty-free agreement will enable supply of generic alimatravir to cover 129 Low- & Middle-Income Countries (LMICs) which account for the majority of new HIV diagnoses globally, subject to applicable regulatory approvals and requirements.

Executing these agreements before Phase 3 trial enrollment is completed is a first in HIV prevention and is intended to enable the right scale-up where Aurobindo Pharma is licensed to manufacture and supply generic alimatravir, which will meet internationally recognized standards following regulatory approvals.

"At Aurobindo Pharma, expanding access to high-quality, affordable medicines remains central to our purpose. Our collaboration with MSD reflects our continued commitment to partnering with innovators to accelerate equitable access to potential new therapies. Through this voluntary licensing agreement, we look forward to making alimatravir available across eligible low- and middle-income countries, subject to successful development and regulatory approvals, helping strengthen global efforts towards HIV prevention." said Umesh K, Associate President & Head - Global Access & Licensing.

"We are pleased to be working with Aurobindo and the other manufacturers involved in these voluntary licensing agreements to manufacture generic alimatravir in 129 LMICs, if approved," said Gregg Szabo, senior vice president, Global HIV Marketing, MSD. "We hope this early action will help stakeholders across the HIV response begin planning for the scale-up needed to reach people who could benefit from HIV prevention, following the necessary regulatory approvals."

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 1531.50 as compared to the previous close of Rs. 1523.90. The total number of shares traded during the day was 21044 in over 1819 trades.

The stock hit an intraday high of Rs. 1540.65 and intraday low of 1513.15. The net turnover during the day was Rs. 32206861.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 Pharmaceuticals VoluntaryLicenseAgreement MSD NonExclusive